Neurotargeting
Advances in molecular neurobiology now provide possibilities for the development of new therapies designed for treatment of neurological and psychiatric disorders. Since this type of translational research requires competency in both basic molecular research and experience in practical treatment, the Neurotargeting research group has a broad range of expertise. The group, which is localised in Laboratorium A, 5th floor in the Department of Biomedicine, consists of a total of about 20 persons.
Collaboration
In addition to the ongoing in-house research programmes members of the Neurotargeting research group are also involved in local, national and international collaborative research projects.
Permanent members of the academic staff are Professors Jan Haavik, Ian F. Pryme and Anni Vedeler. Dr. Beate Stern, CEO/CSO in the biotech R&D company UniTargetingResearch AS, which is co-localised with the Neurotargeting research group in Laboratorium A, holds a 20% temporary Associate Professor position at the University of Bergen. Professor Ian F. Pryme holds a 20% position in UniTargetingResearch AS. The group otherwise consists of post-doctoral workers, PhD and master students, research-programme based medical students and technical staff.